KLRK1 and neoplasm: IL-18 is another cytokine included into TRUCKs and it was shown to improve CAR T-cell antitumor activity and increased NKG2D-positive NK cells tumor infiltration, while reducing the frequency of regulatory T cells and suppressive macrophages in the tumor micro-environment (153–155).